Previous close | 7.15 |
Open | 7.15 |
Bid | 6.90 x N/A |
Ask | 7.15 x N/A |
Day's range | 6.90 - 7.15 |
52-week range | 4.20 - 12.50 |
Volume | |
Avg. volume | 17 |
Market cap | 1.764B |
Beta (5Y monthly) | 0.06 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.92 |
Earnings date | 05 Aug 2024 - 09 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 59.38 |
On June 7, 2024, Steven Cohen (Trades, Portfolio)'s firm made a significant addition to its investment portfolio by acquiring 6,647,015 shares of Maravai LifeSciences Holdings Inc (NASDAQ:MRVI). This move has increased the firm's stake in Maravai LifeSciences to 5.00% of the total shares outstanding, reflecting a strategic position with a 0.14% portfolio weight and a trade impact of 0.11%. Steven A. Cohen, Chairman and CEO of Point72, a prominent investment advisor, has a distinguished career in the financial markets.
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
SAN DIEGO, May 13, 2024--TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and therapeutic development, leveraging TriLink’s leading RNA synthesis technology.